Small Cell Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The timing of initiation to immunotherapy, either with the first cycle of chemotherapy or within 21 days of diagnosis, does not significantly affect outcomes in ES-SCLC. | Image Credit: Bonsales - stock.adobe.com
Immunotherapy Timing Does Not Significantly Affect Outcomes in ES-SCLC

June 12th 2025

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com
Novel Biomarkers May Inform Prognosis in SCLC

June 6th 2025

With inconclusive treatment guidance and varying findings from clinical trials, the prognosis of transformed SCLC remains poor. | Image credit: Crystal Light - stock.adobe.com
Whole Exome Sequencing Identifies Distinct Profile of Transformed SCLC

May 12th 2025

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

Multidisciplinary Approaches to Paraneoplastic LEMS

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.
Continuing Medical Education
View All
June 23rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
June 23rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Sotorasib Shows Benefit for Patients With Certain Type of NSCLC
September 21st 2020

Sotorasib Shows Benefit for Patients With Certain Type of NSCLC

Allison Inserro
The KRAS mutation occurs in 13% of non–small cell lung cancers (NSCLC) and leads to worse outcomes in NSCLC.
Dr Melissa Johnson: COVID-19 Has Brought About Lasting Change to Medicine
September 18th 2020

Dr Melissa Johnson: COVID-19 Has Brought About Lasting Change to Medicine

Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute and partner in Tennessee Oncology, speaks on changes necessitated by the coronavirus disease 2019 (COVID-19) pandemic and connecting virtually.
Image of lung cancer
September 17th 2020

Pandemic Altered Treatment Plans for Patients With Lung Cancer, Study Finds

Allison Inserro
More than half of the patients in this study, with either non–small or small cell lung cancer, experienced changes in their treatment plan during the coronavirus disease 2019 pandemic this spring.
Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC
September 9th 2020

Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC

Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute and partner in Tennessee Oncology, discusses the potential of tiragolumab/atezolizumab for metastatic non–small cell lung cancer (NSCLC).
Dr Melissa Johnson: Treatment Advances Highlight the Immune System’s Importance in Lung Cancer
September 1st 2020

Dr Melissa Johnson: Treatment Advances Highlight the Immune System’s Importance in Lung Cancer

Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute and partner in Tennessee Oncology, discussed the biggest gains in the lung cancer space that have contributed to improved survival for patients.
<1
...
678910

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo